Italia markets closed

Arrowhead Pharmaceuticals, Inc. (0HI3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
32,79+0,64 (+1,98%)
Alla chiusura: 03:33PM GMT
Schermo intero
Chiusura precedente32,15
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume1.092
Media VolumeN/D
Capitalizzazione32,175M
Beta (5 anni mensile)1,09
Rapporto PE (ttm)N/D
EPS (ttm)-1,08
Prossima data utili06 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

    Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd